Proteomic markers in breast cancer diagnosis and treatment
-
Published:2022-12-31
Issue:03
Volume:68
Page:355-356
-
ISSN:1857-8969
-
Container-title:Macedonian Pharmaceutical Bulletin
-
language:en
-
Short-container-title:Maced. Pharm. Bull.
Author:
Djokoski Filip1, Kadifkova Panovska Tatjana1, Hiljadnikova-Bajro Marija1
Affiliation:
1. Faculty of Pharmacy, Institute of Applied Biochemistry, Ss. Cyril and Methodius University in Skopje, Mother Theresa 47, 1000 Skopje, Republic of North Macedonia
Publisher
Macedonian Pharmaceutical Association
Reference12 articles.
1. Bel'skaya, L.V., Sarf, E.A., Solomatin, D.V., Kosenok, V.K., 2022. Metabolic features of saliva in breast cancer patients. Metabolites 12(2), 166. https://doi.org/10.3390/metabo12020166 2. Falchook, G., Infante, J., Arkenau, H.T., Patel, M.R., Dean, E., Borazanci, E., Brenner, A., Cook, N., Lopez, J., Pant, S., Frankel, A., Schmid, P., Moore, K., McCulloch, W., Grimmer, K., O'Farrell, M., Kemble, G., Burris, H., 2021. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. E Clin. Med. 34, 100797. https://doi.org/10.1016/j.eclinm.2021.100797 3. Gruslova, A., McClellan, B., Balinda, H.U., Viswanadhapalli, S., Alers, V., Sareddy, G.R., Huang, T., Garcia, M., deGraffenried, L., Vadlamudi, R.K., Brenner, A.J., 2021. FASN inhibition as a potential treatment for endocrine-resistant breast cancer. Breast Cancer Res. Treat.187(2), 375-386. https://doi.org/10.1007/s10549-021-06231-6 4. Lovely, B., 2022. Targeting CD166 represents a new avenue of attack for breast cancer. OncologyLive [online] 23(01), pp.40. Available at: www.onclive.com/view/targeting-cd166-represents-a-new-avenue-of-attack-for-breast-cancer (Accessed on:28.05. 2022) 5. Patuleia, S., Suijkerbuijk, K., van der Wall, E., van Diest, P.J., Moelans, C.B., 2022. Nipple aspirate fluid at a glance. Cancers 14(1), 159. https://doi.org/10.3390/cancers14010159
|
|